Louisiana well being care staff and advocates filed a lawsuit Thursday difficult a just lately handed state legislation reclassifying two medication utilized in treatment abortions — mifepristone and misoprostol — as managed and harmful substances.
The lawsuit was filed in Louisiana’s nineteenth Judicial District Court docket and is looking for an injunction to cease the state from implementing Act 246, which lists the drugs as Schedule IV managed and harmful substances.
That classification is often used for medication which have a low threat of resulting in bodily dependence or a low threat for potential for abuse like Xanax, Valium and Ambien.
Louisiana grew to become the primary state to go a legislation classifying the 2 drugs as managed substances in Could and it went into impact Oct. 1.
Mifepristone and misoprostol are generally utilized in treatment abortions however are additionally used to deal with circumstances associated to being pregnant like miscarriages or postpartum hemorrhaging in addition to Cushing’s syndrome and gastric ulcers.
For some postpartum hemorrhage sufferers with preexisting circumstances, misoprostol is the one accessible remedy, the lawsuit reads, including that the situation is as “dangerous as a gunshot wound.”
“Patients experiencing postpartum hemorrhage lose as much blood, and as quickly, as patients suffering from a gunshot wound,” the lawsuit reads.
Plaintiffs stated within the lawsuit the legislation has little if any affect on abortion entry since abortion is sort of totally banned within the state.
Louisiana was certainly one of 13 states to start implementing a set off abortion ban, prohibiting abortions in any respect levels of being pregnant with few exceptions, after the 2022 overturning of Roe v. Wade.
As a substitute, plaintiffs argue, the legislation topics well being care suppliers and their sufferers to a “highly regulated legal scheme” that delays entry to doubtlessly lifesaving treatment.
Physicians in Louisiana want a particular license to prescribe managed substances and state officers monitor prescribers and the sufferers receiving the medication together with the pharmacies that distribute them.
Each medication are nonetheless accessible in hospitals to deal with incomplete miscarriages and postpartum hemorrhaging however have to be securely saved in a locked “cabinet, compartment or other system,” in response to the Louisiana Division of Well being.
The Louisiana Division of Well being has but to reply to a request for touch upon the lawsuit.
Below the present legislation, a prescription from a licensed supplier is required to entry each mifepristone and misoprostol. Anybody present in possession of the medication and not using a prescription might be fined as much as $5,000 or sentenced to as much as 5 years in jail.
The lawsuit additionally challenges the way in which through which Louisiana handed Act 246 with plaintiffs claiming lawmakers didn’t observe the state’s constitutional course of for passing payments.
“Access to safe, timely, and effective care is essential to reducing maternal mortality, especially for Black women who face higher rates of life-threatening complications,” one of many plaintiffs within the lawsuit, the Birthmark Doula Collective, stated in a press release.
“Restricting access to this essential medication not only endangers lives but also deepens the health disparities that disproportionately affect Black mothers and birthing people in our state.”
